OpACIN与OpACIN-neo试验中新辅助伊匹木单抗联合纳武利尤单抗治疗大体量III期黑色素瘤的生存更新
两项试验评估新辅助伊匹木单抗联合纳武利尤单抗治疗大体量III期黑色素瘤的长期生存。中位随访69个月(OpACIN)和47个月(OpACIN-neo),中位无复发生存期和总生存期均未达到。病理缓解是疾病复发的最强预测因素。
要点
- OpACIN新辅助组5年无复发生存率和总生存率估计为70%和90%,辅助组为60%和70%。
- OpACIN-neo 3年无复发生存率和总生存率估计分别为82%和92%。
- 病理缓解患者3年无复发生存率估计为95%,无病理缓解者为37%(P < 0.001)。
核心结论
- 更新数据证实新辅助联合检查点抑制在大体量III期黑色素瘤中具有高生存率,尤其是病理缓解患者。
- 病理缓解是长期结局的最强替代标志物。
研究设计与样本
- OpACIN试验将20例大体量III期黑色素瘤患者随机分配至伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg每3周一次,共4周期辅助治疗,或分割为2周期新辅助和2周期辅助治疗。
- OpACIN-neo试验将86例大体量III期黑色素瘤患者随机分配至A组(2次伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg每3周一次;n = 30)、B组(2次伊匹木单抗1 mg/kg联合纳武利尤单抗3 mg/kg每3周一次;n = 30)或C组(2次伊匹木单抗3 mg/kg每3周一次联合2次纳武利尤单抗3 mg/kg每2周一次;n = 26),随后手术。
主要发现
- 两项试验的中位无复发生存期和总生存期均未达到。
- OpACIN中位随访69个月,新辅助治疗有病理缓解的7例患者中1例疾病复发。
- OpACIN新辅助组5年无复发生存率和总生存率估计为70%和90%,辅助组为60%和70%。
- OpACIN-neo中位随访47个月,3年无复发生存率和总生存率估计分别为82%和92%。
- OpACIN-neo有病理缓解患者3年无复发生存率估计为95%,无病理缓解患者为37%(P < 0.001)。
关键数值与推荐
- OpACIN:新辅助组5年无复发生存率70%、总生存率90%;辅助组5年无复发生存率60%、总生存率70%。
- OpACIN-neo:3年无复发生存率82%、总生存率92%。
- OpACIN-neo:有病理缓解患者3年无复发生存率95% vs 无病理缓解患者37%(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in patients with macroscopic stage III melanoma. These response rates translated to high short-term survival rates. However, data on long-term survival and disease recurrence are lacking. PATIENTS AND METHODS: In OpACIN, 20 patients with macroscopic stage III melanoma were randomized to ipilimumab 3 mg/kg plus nivolumab 1 mg/kg q3w four cycles of adjuvant or split two cycles of neoadjuvant and two adjuvant. In OpACIN-neo, 86 patients with macroscopic stage III melanoma were randomized to arm A (2× ipilimumab 3 mg/kg plus nivolumab 1 mg/kg q3w; n = 30), arm B (2× ipilimumab 1 mg/kg plus nivolumab 3 mg/kg q3w; n = 30), or arm C (2× ipilimumab 3 mg/kg q3w plus 2× nivolumab 3 mg/kg q2w; n = 26) followed by surgery. RESULTS: The median recurrence-free survival (RFS) and overall survival (OS) were not reached in either trial. After a median follow-up of 69 months for OpACIN, 1/7 patients with a pathologic response to neoadjuvant therapy had disease recurrence. The estimated 5-year RFS and OS rates for the neoadjuvant arm were 70% and 90% versus 60% and 70% for the adjuvant arm. After a median follow-up of 47 months for OpACIN-neo, the estimated 3-year RFS and OS rates were 82% and 92%, respectively. The estimated 3-year RFS rate for OpACIN-neo was 95% for patients with a pathologic response versus 37% for patients without a pathologic response (P < 0.001). In multiple regression analyses, pathologic response was the strongest predictor of disease recurrence. Of the 12 patients with distant disease recurrence after neoadjuvant therapy, 5 responded to subsequent anti-PD-1 and 8 to targeted therapy, although 7 patients showed progression after the initial response. CONCLUSIONS: Updated data confirm the high survival rates after neoadjuvant combination checkpoint inhibition in macroscopic stage III melanoma, especially for patients with a pathologic response. Pathologic response is the strongest surrogate marker for long-term outcome.
引用
- Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023. PMID: 36681299. doi:10.1016/j.annonc.2023.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。